New release on the women’s health front, Nexstellis tablet expands Organon’s US contraceptive lineup

Organon is leaning further into women’s health with Nexstellis, a next-generation combined oral contraceptive that uses estetrol, a naturally occurring estrogen, as its key differentiator in the crowded birth-control pill market.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/15/2026 at 10:21 PM ET. Details in the imprint.

With a crowded US contraceptive market, Organon is betting on differentiation: Nexstellis, a combined oral contraceptive tablet co-marketed with Mayne Pharma, uses estetrol - a naturally occurring estrogen - as its central selling point and has been steadily rolling out across US pharmacies since its 2021 approval, giving the company a fresh angle in women’s health.

What Nexstellis does differently from traditional birth-control pills

Nexstellis (drospirenone/estetrol) is a once-daily combined oral contraceptive that pairs drospirenone, a progestin widely used in other pills, with estetrol, a native estrogen produced by the human fetal liver and present during pregnancy, with the aim of delivering effective contraception with a distinct estrogen profile. According to the official Nexstellis prescribing information, the product is indicated for use in females of reproductive potential to prevent pregnancy and is supplied as blister packs containing 24 active tablets and 4 inactive tablets per cycle. Unlike many older combined pills that use ethinyl estradiol as the estrogen component, Nexstellis relies on estetrol (E4), which Organon and its partners highlight for its selective estrogen receptor activity and differentiated pharmacology.

Clinical data submitted to the US Food and Drug Administration showed that Nexstellis achieved a Pearl Index - a standard measure of contraceptive effectiveness - in line with other modern combination oral contraceptives when taken as directed, while offering a different safety and tolerability profile tied to estetrol’s unique metabolism and receptor binding characteristics. In trials, commonly reported adverse reactions included bleeding pattern changes, headache and breast pain, consistent with the broader class of combined oral contraceptives, but the estetrol-based formulation is designed to reduce some estrogen-related effects on liver and coagulation parameters compared with ethinyl estradiol-based products. Nexstellis is taken once daily at the same time each day, and missed-dose instructions follow the familiar pattern of most 24/4 combined pills, which may ease switching for patients already used to oral regimens.

Organon positions Nexstellis as part of its broader women’s health-focused portfolio that also includes long-acting reversible contraceptives such as contraceptive implants and intrauterine systems, aiming to offer options ranging from daily pills to multi-year devices. For prescribers, the key talking point is the estetrol component: because estetrol is a natural estrogen present only during pregnancy, researchers have been exploring whether its selective action could translate into specific clinical advantages, though long-term real-world evidence is still accumulating and the product carries the same boxed warnings regarding cigarette smoking and serious cardiovascular events seen with other estrogen-containing contraceptives. As with all combined hormonal contraceptives, Nexstellis is contraindicated in women with high risk of arterial or venous thrombotic disease, certain cancers, or uncontrolled hypertension, and label guidance emphasizes an individualized risk-benefit discussion before prescribing.

Pricing and reimbursement place Nexstellis in the branded oral contraceptive category rather than low-cost generics, making insurance coverage, co-pay programs and formulary placement important drivers of uptake in the US. Organon’s launch communications have stressed the company’s intention to work with payers to secure broad access, and patients can obtain the product via prescription at retail and mail-order pharmacies across the United States, subject to local availability. Because Nexstellis targets a large and recurring-usage category, its commercial performance depends not only on clinical differentiation but also on patient familiarity, physician confidence and competitive positioning against both low-cost generic pills and other branded options that emphasize features such as reduced bleeding or acne benefits.

For Organon, Nexstellis fits into a strategy of building a focused women’s health and biosimilars company following its spin-off from Merck & Co., with contraception, fertility and menopause management as core therapeutic pillars. Recent financial disclosures describe contraception as a significant contributor to the firm’s established brands segment, and newer launches like Nexstellis are expected to help stabilize revenues as older products face competition from generics and alternative therapies. Shares of Organon & Co. (US68622V1061) traded on the NYSE at around $19 per share on 06/13/2026, reflecting investor attention on execution in women’s health, biosimilars and geographic expansion.

Nexstellis brief profile: key facts for users

• Product: Nexstellis (drospirenone/estetrol) tablets
• Manufacturer: Organon & Co.
• Category: New Release - prescription combined oral contraceptive
• Launch date: US commercial launch announced in 2021
• MSRP / Price: Branded prescription pricing; final out-of-pocket cost varies by insurance coverage and pharmacy
• Availability: Prescription only, available through US retail and mail-order pharmacies
• Target audience: Females of reproductive potential seeking an oral contraceptive option and without contraindications to estrogen-containing products
• Key differentiator / USP: Uses estetrol, a naturally occurring estrogen, instead of ethinyl estradiol as the estrogen component in a combined oral contraceptive

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.